Cabaletta Bio

Update in progress

CABA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. Its lead product, resecabtagene autoleucel (CD19-CAR T with a 4-1BB co-stimulatory domain), is in Phase 1/2 for diseases including dermatomyositis, lupus, and multiple sclerosis. DSG3-CAART and MuSK-CAART are in Phase 1 for mucosal pemphigus vulgaris and MuSK-positive myasthenia gravis. Collaborations include UPenn/CHOP, Nanjing IASO, Oxford Biomedica, Autolus, WuXi. Based in Philadelphia; formerly Tycho Therapeutics.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive